

Product Catalog




R³CE[®] Cell Culture Plates and Flasks

Size	Color	Catalog #
6-well	flat bottom clear	T5225006T
12-well	flat bottom clear	T5225012T
24-well	flat bottom clear	T5225024T
96-well	flat bottom clear	T5225096T
	flat clear bottom white	T5225096W
	flat clear bottom black	T5225096B
384-well	on-demand	
T25 Flask	flat bottom clear	T52250T25
T75 Flask	on-demand	

Main Product

R³CE[®] Cell Culture Plates



R³CE[®] Organoid Medium Kit



R³CE[®] CTC Medium



R³CE[®] Cell Culture Medium

Type	Tissue Type	Package Content	Catalog #
Organoid Medium	Basal	Initial medium, 25 mL Maintenance medium, 50 mL	BSLLA003
	GI (Gastrointestinal Tract)	Initial medium, 25 mL Maintenance medium, 50 mL	GITLA003
	Breast	Initial medium, 25 mL Maintenance medium, 50 mL	BRALA003
	Ovarian	Initial medium, 25 mL Maintenance medium, 50 mL	OVALA003
	Liver (Hepatocellular)	Initial medium, 25 mL Maintenance medium, 50 mL	HEPLA003
CTC Medium	Basal	Complete Medium, 50 mL	CTCLA004
	Breast	Complete Medium, 50 mL	CTFLA004

About AcroCyte

AcroCyte Therapeutics bridges the gap between laboratory models and patient-specific medicine. Our core **R³CE[®]** platform is an easy-to-use, scaffold-free system, designated as a Class I FDA device, that rapidly converts minimal patient specimens into functional 3D organoids within days.

This breakthrough empowers advanced downstream workflows, enabling comprehensive functional analysis of clinical and liquid biopsy samples for precision oncology. AcroCyte supports academic, clinical, and industry partners worldwide to accelerate drug discovery, diagnostics, and regenerative medicine with scalable, accessible 3D culture technology.

Why Choose AcroCyte ?



Efficient

Scale 3D culture through a simple, 2D-like workflow, with no specialized equipment.



Extensive

Validated across multiple cancer types and diverse clinical specimens.



Endorsed

Supported by clinical collaboration to enable confident, reliable decision-making.

Taipei, Taiwan

12F-8, No.99, Sec. 1, Xintai 5th Rd.,
Xizhi Dist., New Taipei City 22175,
Taiwan

San Carlos, CA, USA

AcroCyte 1030 Brittan Ave.,
San Carlos, CA 94070,
USA



www.acrocyte.com



AcroCyte Therapeutics, Inc.



info@acrocyte.com



Scaffold-Free
3D Organoid
Culture

Rapid, Reproducible, Rare Cell Expansion
with R³CE[®] Technology



Designed for patient-derived models, translational research, and precision oncology applications.



One Platform for Patient-Derived 3D Culture



1 Workflow Overview



2 Our Core Technologies


R³CE® Technologies : A Rapid, Reproducible, Rare Cell 3D Expansion Platform



From A Single Cell to Scalable 3D Spheroids


Consistent. Reproducible. Discovery-ready.

Colon cancer cell line HCT116
Single cells self-assemble into 3D spheroids over 7 days.




Applications

Breast Cancer PDOs




Breast cancer patient-derived organoids (PDOs) generated from paired tumor and tumor-adjacent normal tissue on R³CE® plates. Representative bright-field images of PDOs derived from breast cancer patient core-needle biopsy specimens, with IHC staining for CK7 and CK20 to confirm breast origin. Cells were cultured with R³CE® organoid medium (#BRALA003). (P: passage number, F: number of free-thaw cycle, D: culture period of given passage)

Colorectal Cancer PDOs




Colorectal-derived PDOs generated from paired tumor and tumor-adjacent normal tissue on R³CE® plates. (A) Representative bright-field images of tissue-derived PDOs from colorectal cancer patients across different stages and pathological backgrounds (P: passage number). (B) H&E histology and IHC staining for Ki67, CK20, and CDX2 to confirm tumor versus normal tissue identity and the colorectal origin of the PDOs. Cells were cultured with R³CE® organoid medium (#GITLA003).

CTC Assay for Precision Oncology




Precision therapy assay on R³CE®-derived circulating tumor cell (CTC) cultures. R³CE®-CTC culture enables functional drug screening to identify effective therapeutic options and predict clinical response. By integrating tumor biology with ex vivo testing, this platform supports precision oncology decision-making, optimizes individualized treatment strategies, and improves clinical outcomes for patients with advanced or treatment-resistant cancers.

Functional ADCC Assay



CTC Assay for Precision Oncology



Case study: R³CE® CTC culture platform guides precision therapy for breast cancer. (A, B) Patient with recurrent luminal breast cancer and lung/liver metastases showed poor response to T-DXd. (C) NGS identified an AKT p.E17K mutation, prompting CTC spheroid drug screening, which revealed sensitivity to mTOR inhibition and taxane-based therapy. (D-G) Treatment with everolimus plus capecitabine (5-Fu) led to liver metastasis regression, along with decreased tumor markers, improved liver function, and disease stabilization for over 12 months.